Centessa Pharmaceuticals (CNTA) Shares Outstanding (Diluted Average) (2021 - 2026)

Centessa Pharmaceuticals (CNTA) has 6 years of Shares Outstanding (Diluted Average) data on file, last reported at $153.5 million in Q1 2026.

• Shares Outstanding (Diluted Average) for Q1 2026 came in at $153.5 million, up 15.42% year-over-year; the trailing twelve-month figure through Mar 2026 was $153.5 million (up 15.42% YoY), and the FY2025 annual result was $135.7 million, up 18.56% from the prior year.
• Shares Outstanding (Diluted Average) climbed to $153.5 million in Q1 2026 per CNTA's latest filing, from $135.7 million in the prior quarter.
• Over five years, Shares Outstanding (Diluted Average) peaked at $153.5 million in Q1 2026 and troughed at $90.5 million in Q1 2022.
• A 5-year average of $109.9 million and a median of $99.9 million in 2024 frame the typical range for Shares Outstanding (Diluted Average).
• The sharpest annual moves came in 2022 and 2023: Shares Outstanding (Diluted Average) surged 88.36% in 2022, then grew 2.79% in 2023.
• A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $93.4 million in 2022, then rose by 2.97% to $96.2 million in 2023, then increased by 19.02% to $114.5 million in 2024, then grew by 18.56% to $135.7 million in 2025, then rose by 13.14% to $153.5 million in 2026.
• Business Quant data shows CNTA's Shares Outstanding (Diluted Average) at $153.5 million in Q1 2026, $135.7 million in Q4 2025, and $134.2 million in Q3 2025.